J
Jonathan Ciron
Researcher at University of Toulouse
Publications - 102
Citations - 1870
Jonathan Ciron is an academic researcher from University of Toulouse. The author has contributed to research in topics: Medicine & Multiple sclerosis. The author has an hindex of 17, co-authored 68 publications receiving 1081 citations. Previous affiliations of Jonathan Ciron include University of Poitiers.
Papers
More filters
Journal ArticleDOI
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
Alvaro Cobo-Calvo,Anne Ruiz,Elisabeth Maillart,Bertrand Audoin,Hélène Zéphir,Bertrand Bourre,Jonathan Ciron,Nicolas Collongues,David Brassat,François Cotton,Caroline Papeix,Françoise Durand-Dubief,David Laplaud,Romain Deschamps,Mikael Cohen,Damien Biotti,Xavier Ayrignac,Caroline Tilikete,Eric Thouvenot,Bruno Brochet,Cécile Dulau,Thibault Moreau,Ayman Tourbah,Pierre Lebranchu,Laure Michel,Christine Lebrun-Frenay,Alexis Montcuquet,Guillaume Mathey,Marc Debouverie,Jean Pelletier,Pierre Labauge,Nathalie Derache,M. Coustans,Fabien Rollot,Jérôme De Seze,Sandra Vukusic,Romain Marignier +36 more
TL;DR: In adults, MOG-Ab-associated disease extends beyond clinical and radiologic abnormalities in the optic nerve and spinal cord and despite the relapsing course, the overall visual and motor outcome is better compared with AQP4- Ab-positive patients.
Journal ArticleDOI
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
Daniel Whittam,Daniel Whittam,Alvaro Cobo-Calvo,A. Sebastian Lopez-Chiriboga,Santiago Pardo,Matthew Gornall,Silvia Cicconi,Alexander U. Brandt,Klaus Berek,Thomas Berger,Ilijas Jelcic,Grace Y. Gombolay,Luana Micheli Oliveira,Dagoberto Callegaro,Kimihiko Kaneko,Tatsuro Misu,Marco Capobianco,Emily Gibbons,Venkatraman Karthikeayan,Bruno Brochet,Bertrand Audoin,Guillaume Mathey,David Laplaud,Eric Thouvenot,Mikael Cohen,Ayman Tourbah,Elisabeth Maillart,Jonathan Ciron,Romain Deschamps,Damien Biotti,Kevin Rostasy,Rinze F. Neuteboom,Cheryl Hemingway,Rob Forsyth,Marcelo Matiello,Stewart Webb,David M. Hunt,Katy Murray,Yael Hacohen,Ming K. Lim,M. Isabel Leite,Jacqueline Palace,Tom Solomon,Andreas Lutterotti,Kazuo Fujihara,Ichiro Nakashima,Jeffrey Bennett,Lekha Pandit,Tanuja Chitnis,Brian G. Weinshenker,Brigitte Wildemann,Douglas Kazutoshi Sato,Su Hyun Kim,Saif Huda,Ho Jin Kim,Markus Reindl,Michael J. Levy,Sven Jarius,Silvia Tenembaum,Friedemann Paul,Sean J. Pittock,Romain Marignier,Anu Jacob,Anu Jacob,Anu Jacob +64 more
TL;DR: RTX reduced relapse rates in MOGAD, however, many patients continued to relapse despite apparent B-cell depletion, and Prospective controlled studies are needed to validate these results.
Journal ArticleDOI
Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Alvaro Cobo-Calvo,Maria Sepúlveda,Fabien Rollot,Thaís Armangue,Anne Ruiz,Elisabeth Maillart,Caroline Papeix,Bertrand Audoin,Hélène Zéphir,Damien Biotti,Jonathan Ciron,Françoise Durand-Dubief,Nicolas Collongues,Xavier Ayrignac,Pierre Labauge,Eric Thouvenot,Bertrand Bourre,Alexis Montcuquet,Mikael Cohen,Romain Deschamps,Nuria Sola-Valls,Sara Llufriu,Jérôme De Seze,Yolanda Blanco,Sandra Vukusic,Albert Saiz,Romain Marignier +26 more
TL;DR: In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes and such an effect was not found in the few patients treated with MS-DMD.
Journal ArticleDOI
Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Alvaro Cobo-Calvo,Alvaro Cobo-Calvo,Anne Ruiz,Fabien Rollot,Georgina Arrambide,Romain Deschamps,Elisabeth Maillart,Caroline Papeix,Bertrand Audoin,Anne Lepine,Hélène Maurey,Hélène Zéphir,Damien Biotti,Jonathan Ciron,Françoise Durand-Dubief,Nicolas Collongues,Xavier Ayrignac,Pierre Labauge,Pierre Meyer,Eric Thouvenot,Bertrand Bourre,Alexis Montcuquet,Mikael Cohen,Philippe Horello,Mar Tintoré,Jérôme De Seze,Sandra Vukusic,Sandra Vukusic,Kumaran Deiva,Romain Marignier +29 more
TL;DR: The main objective was to compare clinical features, disease course, and myelin oligodendrocyte glycoprotein (Mog) antibody (Ab) dynamics between children and adults with MOG‐Ab–associated disease (MOGAD).
Journal ArticleDOI
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
Hélène Zéphir,Raphaël Bernard-Valnet,Christine Lebrun,Olivier Outteryck,Bertrand Audoin,Bertrand Bourre,Sophie Pittion,Sandrine Wiertlewski,J.-C. Ouallet,Jean-Philippe Neau,Jonathan Ciron,Pierre Clavelou,Romain Marignier,David Brassat +13 more
TL;DR: A retrospective analysis of NMO patients from NOMADMUS network found 32 patients receiving rituximab as first-line therapy with a mean follow-up of 28.7 ± 21 months, twenty-seven patients were relapse free and patients presented a 97 % decrease of ARR and EDSS.